This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brewer, M. Articles by Wharton, J. T. Search for Related Content PubMed PubMed Citation Articles by Brewer, M. Articles by Wharton, J. T. Social Bookmarking                            What's this?

Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma

From the Departments of Gynecologic Oncology, Pediatrics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to David M. Gershenson, MD, Department of Gynecologic Oncology, Box 67, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; email dgershen{at}mdanderson.org

PURPOSE: To review the outcome for all patients with ovarian dysgerminoma treated at the M.D. Anderson Cancer Center who received bleomycin, etoposide, and cisplatin (BEP) and to assess the menstrual and reproductive function of those who received conservative treatment.

PATIENTS AND METHODS: Clinical information was abstracted from the medical record. Patients completed a detailed questionnaire about menstrual and reproductive function; those who did not return the questionnaire were interviewed by telephone.

RESULTS: Twenty-six patients were identified as having been treated with BEP chemotherapy for pure ovarian dysgerminoma from January 1984 to January 1998. Their median age was 19.5 years (range, 7 to 32 years). Sixteen patients underwent fertility-sparing surgery in the form of unilateral salpingo-oophorectomy. At a median follow-up time of 89 months, 25 (96%) of the 26 patients remained continuously disease-free. One patient apparently developed a second primary dysgerminoma in her remaining ovary after BEP and was clinically disease-free after further treatment. Of the 16 patients who underwent fertility-sparing surgery, one was lost to follow-up when she was pregnant, and one was still premenarchal. Of the remaining 14 patients, 10 (71%) maintained their normal menstrual function during and after chemotherapy, and 13 (93%) had returned to their prechemotherapy menstrual pattern at the time of the questionnaire. Five pregnancies have occurred thus far, and two patients have had difficulty conceiving.

CONCLUSION: Most patients with metastatic dysgerminoma can expect cure with maintenance of normal reproductive function when treated with conservative surgery and BEP chemotherapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. de La Motte Rouge, P. Pautier, P. Duvillard, A. Rey, P. Morice, C. Haie-Meder, P. Kerbrat, S. Culine, F. Troalen, and C. Lhomme Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor Ann. Onc., August 1, 2008; 19(8): 1435 - 1441. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]

				D. M. Gershenson, A. M. Miller, V. L. Champion, P. O. Monahan, Q. Zhao, D. Cella, and S. D. Williams Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2792 - 2797. [Abstract] [Full Text] [PDF]

				Y. Kitajima, T. Endo, T. Hayashi, S. Ishioka, T. Baba, H. Honnma, and T. Saito A successful IVF-pregnancy in a patient who underwent conservative surgery followed by a regimen of cisplatin, vinblastine and peplomycin to treat an advanced ovarian mixed germ cell tumour: A Case Report Hum. Reprod., March 1, 2007; 22(3): 850 - 852. [Abstract] [Full Text] [PDF]

				M. Sonmezer and K. Oktay Fertility preservation in young women undergoing breast cancer therapy. Oncologist, May 1, 2006; 11(5): 422 - 434. [Abstract] [Full Text] [PDF]

				B. Simon, S. J. Lee, A. H. Partridge, and C. D. Runowicz Preserving Fertility After Cancer CA Cancer J Clin, July 1, 2005; 55(4): 211 - 228. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Fertility-Sparing Surgery for Malignancies in Women J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 43 - 47. [Abstract] [Full Text] [PDF]

				M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]

				G. Zanetta, C. Bonazzi, M. G. Cantu, A. Locatelli, G. Bratina, and C. Mangioni Survival and Reproductive Function After Treatment of Malignant Germ Cell Ovarian Tumors J. Clin. Oncol., February 15, 2001; 19(4): 1015 - 1020. [Abstract] [Full Text] [PDF]

				M. R. Laufer Reproductive Issues for Cancer Patients/Survivors J. Clin. Oncol., September 1, 1999; 17(9): 2631 - 2631. [Full Text] [PDF]